Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
mlys · stock forecast · 8 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$56.00
Consensus
$46.00
+101.9% upside
Low
$30.00
Median: $52 · Last Close: $22.78
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$46.00
101.9% upside
High Target
$56
145.8%
Low Target
$30
31.7%
Current Price
$22.78
as of today
Based on analyst price targets, the MLYS stock price prediction for the next 12 months ranges from $30 to $56. The consensus MLYS price forecast of $46.00 implies 101.9% upside from the current price of $22.78.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $21.64 | ↓ 5.00% |
1-day model range: $21.45–$21.83. Peak: $21.83 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · MLYS · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-13 | B of A Securities | Maintains | Buy→Buy |
| 2025-12-19 | Stifel | Maintains | Buy→Buy |
| 2025-11-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-11 | Wells Fargo | Maintains | Overweight→Overweight |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-11 | Wells Fargo | Maintains | Overweight→Overweight |
| 2025-09-09 | Goldman Sachs | Maintains | Buy→Buy |
| 2025-09-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-03 | Jefferies | Maintains | Hold→Hold |
| 2025-08-28 | B of A Securities | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Mineralys Therapeutics, Inc. (MLYS) stock. Of the recent 24 rating actions, 0 were upgrades and 0 were downgrades. 8 analysts currently cover MLYS.
Analyst Recommendation Trends
MLYS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 99.8% YoY
Revenue Next Year
$121M
↑ 21687.0% YoY
EPS This Year
$-2.31
EPS Next Year
$-2.10
↓ 9.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast MLYS EPS of $-2.31 for the current fiscal year, based on estimates from 6 analysts. The MLYS revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MLYS stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MLYS price target is $46.00 (+101.9% upside), with an analyst consensus of Buy.
The MLYS short-term stock prediction for tomorrow is $21.64 (-5.00%).
Mineralys Therapeutics, Inc. trades on NASDAQ under the ticker MLYS. The MLYS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 88% of covering analysts.
Frequently asked questions
MLYS forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month MLYS price target is $46.00, with a high forecast of $56.00 and a low of $30.00. The median price target is shown in the chart above when available. This implies +101.9% potential upside from the current price of $22.78.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.